Efficacy News and Research

RSS

Study confirms ability of Tru-D device to decontaminate surfaces in patient rooms

In an original article coauthored by John M. Boyce, MD; Nancy L. Havill, MT; and Brent A. Moore, PhD, "Terminal Decontamination of Patient Rooms Using an Automated Mobile UV Light Unit", the research team from the Hospital of Saint Raphael and the Yale University School of Medicine ". . . demonstrated that an automated, portable UV light device significantly reduced aerobic colony counts on high-touch surfaces in patient rooms.

12 Aug 2011

CPAP withdrawal leads to return of obstructive sleep apnea

The benefits of continuous positive airway pressure machines (CPAP) for patients with obstructive sleep apnea (OSA) are quickly reversed when the therapy is withdrawn, according to Swiss research.

12 Aug 2011

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

Affymax, Inc. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide New Drug Application.

12 Aug 2011

Pacira second quarter total revenues increase to $3.6 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and updated its 2011 financial guidance.

11 Aug 2011

Researchers identify unknown link between migration of WBCs to infected tissues, immune memory

Researchers from Dr. Woodland's lab at the Trudeau Institute have now identified a previously unknown link between the migration of white blood cells to infected tissues and the ability of these cells to survive and become long-lived memory cells after the infection has been cleared.

11 Aug 2011

Anticoagulation service improves quality of care for patients treated with warfarin

A pharmacist-directed anticoagulation service improves the coordination of care from the hospital to an outpatient clinic for patients treated with the anticoagulant drug warfarin, according to a Henry Ford Hospital study.

11 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

Aeras, OETC announce initiation of new TB vaccine Phase IIb trial in patients with HIV

Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus.

11 Aug 2011

BELLUS Health second quarter revenues increase to $719,000

BELLUS Health Inc. reported today its financial results for the second quarter ended June 30, 2011.

10 Aug 2011

FDA approves Abbott's RX Herculink Elite Renal Stent System for renal artery stenosis

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high blood pressure).

10 Aug 2011

Glenmark commences Revamilast Phase IIb trial in chronic inflammatory disorders

Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.

10 Aug 2011

Trastuzumab drug increases risk of heart problems in elderly breast cancer patients

The first study to investigate the effect of the breast cancer drug trastuzumab (Herceptin) on heart and vascular function in elderly patients has found that it increases the risk of heart problems, particularly in women with a history of heart disease, diabetes or both.

10 Aug 2011

Nottingham researchers to develop new early warning system for Alzheimer's

Researchers at The University of Nottingham have been awarded £670,000 to develop a new early warning system for Alzheimer's disease.

9 Aug 2011

GTx reports revenue of $1.6 million for second quarter 2011

GTx, Inc. today reported financial results for the second quarter of 2011. The net loss for the quarter ended June 30, 2011 was $10.7 million compared with a net loss of $12.9 million for the quarter ended June 30, 2010.

9 Aug 2011

New preclinical approach can guide more efficient drug development for brain-related conditions

The development of drugs for brain-related conditions is not an efficient process; only 8% of candidate drugs that enter clinical trials gain FDA approval. A key reason for this low success rate is a lack of preclinical tests that accurately predict drug efficacy and detect unwanted side effects.

9 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011

Genentech, Array BioPharma sign oncology agreement for ChK-1 development program

Array BioPharma today announced an oncology agreement with Genentech, a member of the Roche Group, for the development of each company's small-molecule Checkpoint kinase 1 (ChK-1) program.

9 Aug 2011

Soy useless for menopause

In their two year study they found that there were no differences in changes in bone density or menopausal symptoms between women taking soy and those taking a placebo, although women taking isoflavones did have more hot flashes, Dr. Silvina Levis of the University of Miami and colleagues reported in the August 8/22 issue of Archives of Internal Medicine.

8 Aug 2011

AMRI second quarter total revenue increases 9% to $53.9 million

AMRI today reported financial and operating results for the second quarter ended June 30, 2011.

8 Aug 2011

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

8 Aug 2011

Efficacy News and Research

Study confirms ability of Tru-D device to decontaminate surfaces in patient rooms

CPAP withdrawal leads to return of obstructive sleep apnea

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

Pacira second quarter total revenues increase to $3.6 million

Researchers identify unknown link between migration of WBCs to infected tissues, immune memory

Anticoagulation service improves quality of care for patients treated with warfarin

FDA approves Gilead's Complera for treatment of HIV-1 infection

Aeras, OETC announce initiation of new TB vaccine Phase IIb trial in patients with HIV

BELLUS Health second quarter revenues increase to $719,000

FDA approves Abbott's RX Herculink Elite Renal Stent System for renal artery stenosis

Glenmark commences Revamilast Phase IIb trial in chronic inflammatory disorders

Trastuzumab drug increases risk of heart problems in elderly breast cancer patients

Nottingham researchers to develop new early warning system for Alzheimer's

GTx reports revenue of $1.6 million for second quarter 2011

New preclinical approach can guide more efficient drug development for brain-related conditions

Lexicon's second quarter revenues decrease 55% to $0.6 million

Genentech, Array BioPharma sign oncology agreement for ChK-1 development program

Soy useless for menopause

AMRI second quarter total revenue increases 9% to $53.9 million

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News